![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 14-Feb-2013[ | E-mail |
Share ] Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Amsterdam, February 14, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in its journal Maturitas on lichen sclerosus with summary recommendations.
Vulvar lichen sclerosus (LS) is a chronic inflammatory disease which affects genital labial, perineal and perianal areas, producing significant discomfort and psychological distress. The purpose of this clinical guide is to provide advice on early recognition and treatment to prevent delay in management. Women presenting with vulvar pruritus and pain should be examined by a health professional with expertise in vulvar skin disorders. First line treatment is a topical corticosteroid cream and calcineurin inhibitors are second line. Surgical management such as vulvectomy or cryosurgery is reserved for women with malignancy or post-inflammatory sequelae.
These and other recommendations presented in the EMAS clinical guide are published in the article: 'EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women by Faustino R. Prez-Lpez, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Margaret Rees, Karin Schenck-Gustafsson, Florence Tremollieres, Yvonne T. van der Schouw and Tommaso Simoncini.' (doi:10.1016/j.maturitas.2012.12.006). The article appears in Maturitas Volume 74, Issue 3 (March 2013) published by Elsevier.
###
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. www.emas-online.org
About Maturitas
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. www.maturitas.org
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 14-Feb-2013[ | E-mail |
Share ] Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier
Amsterdam, February 14, 2013 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in its journal Maturitas on lichen sclerosus with summary recommendations.
Vulvar lichen sclerosus (LS) is a chronic inflammatory disease which affects genital labial, perineal and perianal areas, producing significant discomfort and psychological distress. The purpose of this clinical guide is to provide advice on early recognition and treatment to prevent delay in management. Women presenting with vulvar pruritus and pain should be examined by a health professional with expertise in vulvar skin disorders. First line treatment is a topical corticosteroid cream and calcineurin inhibitors are second line. Surgical management such as vulvectomy or cryosurgery is reserved for women with malignancy or post-inflammatory sequelae.
These and other recommendations presented in the EMAS clinical guide are published in the article: 'EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women by Faustino R. Prez-Lpez, Iuliana Ceausu, Herman Depypere, C. Tamer Erel, Irene Lambrinoudaki, Margaret Rees, Karin Schenck-Gustafsson, Florence Tremollieres, Yvonne T. van der Schouw and Tommaso Simoncini.' (doi:10.1016/j.maturitas.2012.12.006). The article appears in Maturitas Volume 74, Issue 3 (March 2013) published by Elsevier.
###
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. www.emas-online.org
About Maturitas
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. www.maturitas.org
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-02/e-mpa021413.php
Kate Middleton Nude Photos glee glee boxing news Coptic Christian saturday night live julio cesar chavez jr
No comments:
Post a Comment